II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

Ekaterini Simões Goudouris1, Almerinda Maria do Rego Silva2, Aluce Loureiro Ouiricuri3, Anete Sevciovc Grumach4, Antonio Condino-Neto5, Beatriz Tavares Costa-Carvalho6, Carolina Cardoso de Mello Prando7, Cristina Maria Kokron8, Dewton de Moraes Vasconcelos9, Fabiola Scancetti Tavares9, Gesmar Rodrigues Silva Segundo10, Irma Cecília Douglas Paes Barreto11, Mayra de Barros Dorna8, Myrthes Anna Maragna Toledo Barros8, Wilma Carvalho Neves Forte12; in name of Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology

ABSTRACT
In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1st Brazilian Consensus, published in 2010. The document presents new knowledge about the indications and efficacy of immunoglobulin therapy in primary immunodeficiencies, relevant production-related aspects, mode of use (routes of administration, pharmacokinetics, doses and intervals), adverse events (major, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapeutic resource in Brazil.

Keywords: Immune system diseases; Immunoglobulins; Immunoglobulins, intravenous; Immunologic deficiency syndromes; Immunization, passive

RESUMO
Nos últimos anos, novas imunodeficiências primárias e defeitos genéticos têm sido descritos. Recentemente, produtos de imunoglobulina, com aprimoramento em sua composição e para uso por via subcutânea, tornaram-se disponíveis em nosso meio. Com o objetivo de orientar o médico no uso da imunoglobulina humana para o tratamento das imunodeficiências primárias, os membros do Grupo de Assessoria em Imunodeficiências da Associação Brasileira de Alergia e Imunologia produziram um documento que teve por base uma revisão narrativa da literatura e sua experiência profissional, atualizando o I Consenso Brasileiro publicado em 2010. Apresentam-se novos conhecimentos sobre indicações eficácia do tratamento com imunoglobulina nas imunodeficiências primárias, aspectos relevantes sobre a produção,

1 Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
2 Universidade Federal de Pernambuco, Recife, PE, Brazil.
3 Hospital Servidores do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
4 Faculdade de Medicina do ABC, Santo André, SP, Brazil.
5 Universidade de São Paulo, São Paulo SP, Brazil.
6 Hospital Infantil Pequeno Príncipe, Curitiba, PR, Brazil.
7 Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
8 Hospital de Base do Distrito Federal, Brasília, DF, Brazil.
9 Universidade Federal de Uberlândia, Uberlândia, MG, Brazil.
10 Centro Universitário do Estado do Pará, Belém, PA, Brazil.
11 Faculdade de Ciências Médicas, Santa Casa de São Paulo, São Paulo, SP, Brazil.

Corresponding author: Ekaterini Simões Goudouris – Instituto de Puericultura e Pediatria Martagão Gesteira - Rua Bruno Lobo, 50 - Cidade Universitária – Zip code: 21941-912 – Rio de Janeiro, RJ, Brazil
Phone: (55 21) 2205-0996 – E-mail: egoudouris@gmail.com
Received on: Aug 19, 2016 – Accepted on: Jan 4, 2017
Conflict of interest: none.

This content is licensed under a Creative Commons Attribution 4.0 International License.
Primary immunodeficiencies (PID) are a very heterogeneous group currently made up of more than 300 diseases caused by genetic mutations, leading to abnormal development and function of the immune system, and are characterized by recurrent infections (either severe or caused by unusual or low-pathogenicity agents), autoimmune or inflammatory manifestations, and a greater predisposition to cancer. In the past few years, new diseases and new genetic defects have been described. Several registries around the world, including the Latin American, show that at least 50% of PIDs predominantly affect antibody production, which is also impaired in other types of immune system defects. (3,7-13) The use of serum from animals or convalescent humans in the treatment and prevention of infectious diseases started at the end of the 19th century. Purification of Immunoglobulin G (IgG) became possible in the 1940’s with the Cohn-Oncley fractionation method, (14) used to produce albumin for the injured during World War II. (15,16) Human Ig replacement therapy was performed for the first time in 1952, by Bruton, in the first patient described with agammaglobulinemia, using the subcutaneous route. (17) In the years that followed, the intramuscular route became the most widely used for Ig replacement. However, this mode of administration is painful, reaches serum concentrations in about 24 hours, and has low bioavailability and less than 50% recovery. (18) With the use of higher doses, side effects, such as chills, fever or even anaphylaxis, occur more frequently. (15) Since the 1960’s, different preparations for intravenous administration have been developed and put to use, but it was only in the late 1970’s and early 1980’s that this route became the route of choice for Ig replacement in PID patients. (16,18,19) In the 1980’s, improvements were made to the production process and composition of this immunobiological for intravenous infusion, allowing the use of higher Ig doses with better infection control, but still with many adverse effects. (18,20) At that point in time, subcutaneous administration started to be reported by several services. (21-27) It has been increasingly used in the last 10 to 15 years, with good clinical results, few adverse effects and other advantages when compared to intravenous, as described later. (28-42) Products for subcutaneous use have been available in Brazil since 2015. In the context of major advancements in the knowledge of PIDs and the production of human Ig, and with new products available in the market, we must update the first consensus published in 2010, which is currently in use in Brazil. OBJECTIVE

To update the 1st Brazilian Consensus on the Use of Human Immunoglobulin in Patients with Primary Immunodeficiencies, published in 2010. The text presents advancements in knowledge of indications and efficacy of Ig replacement in primary immunodeficiencies, in addition to relevant facts about production, mode of use (administration routes, pharmacokinetics, doses and intervals), adverse events (major effects, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapy in Brazil. The use of human Ig in secondary immunodeficiencies or as an immunomodulator in autoimmune and inflammatory diseases is not addressed in this paper. METHODS

A foundation text was prepared by the coordinators of the advisory group, based on scientific publications on the use of Ig in primary immunodeficiencies in the last 10 years, retrieved from PubMed and Google Scholar, as well as relevant textbooks and guidelines, in the form of a narrative literature review. The text was sent by e-mail to the other 14 members of the group, to be expanded and modified so as to reflect the technical and literature-based knowledge as well as the clinical experience of all involved.
A final review of the text was carried out by two specialists in the field who were not part of the group.

**INDICATIONS AND EFFICACY OF HUMAN IMMUNOGLOBULIN IN PRIMARY IMMUNODEFICIENCIES**

Treatment with Ig is currently the leading therapeutic approach in almost 75% of PIDs, i.e. those in which antibody production is impaired, promoting the replacement of immunoglobulin G or IgG. The objectives are to maintain stable and adequate serum concentrations of this type of Ig and achieve good clinical management of patients. (44-48)

The target serum IgG concentration had been set at 500mg/dL in blood samples collected immediately before the infusion, but the clinical monitoring of patients has shown that higher values, approximately 700 to 1,000mg/dL, are more efficient to control infections, particularly pneumonia. Higher target IgG concentrations are especially important in patients with chronic pulmonary disease and bronchiectasis, promoting improved lung function. (55,61-64)

It is important to note that the IgG concentrations required for infection prevention vary among individuals, and the treatment must be individualized to find the doses and serum IgG concentrations leading to good clinical responses in each patient (also known as biological IgG level). “Good clinical control” is defined as a decrease in the number and severity of infectious and inflammatory conditions, and a decrease in hospitalizations and use of antibiotics, preventing certain complications and improving general health and quality of life. In patients with normal IgG concentrations before initiating treatment (specific antibody deficiencies, for example), the clinical response alone is used for adjustment of Ig therapy. (67)

The recommendations of the European Society for Primary Immunodeficiencies (ESID) regarding human Ig replacement are serum IgG<200mg/dL is always an indication, except for patients with transient hypogammaglobulinemia of infancy with no severe infections; serum IgG between 200 and 500mg/dL is an indication in case of antibody production deficiency or recurrent and/or severe infections; serum IgG>500mg/dL is an indication for Ig replacement only when abnormal production of specific antibodies is verified, and recurrent and severe infections are present.

According to these recommendations, the use of human Ig is indicated in all PIDs in case of documented impairment in the production of IgG antibodies. (47,74) However, there are evidence-based indications in some PIDs: abnormal antibody production related to B-cell defects (X-linked agammaglobulinemia, common variable immunodeficiency, defective production of specific antibodies, defects of IgG subclasses with abnormal antibody production), except for selective IgA deficiency, as well as combined immunodeficiencies with or without associated syndromes (severe combined immunodeficiencies, X-linked hyper-IgM syndrome, X-linked lymphoproliferative syndrome, Wiskott-Aldrich syndrome, NEMO deficiency, WHIM syndrome, WHIM syndrome - warts, hypogammaglobulinemia and immunodeficiency), and after hematopoietic stem cell transplant in PID patients. (47,74-79) There is some evidence of benefits in hyper-IgE syndrome, ataxia-telangiectasia, DiGeorge syndrome and anticytokine-autoantibody-mediated disorders (Chart 1). The immunoglobulin may also be used as an immunomodulator, at higher doses, to treat autoimmune manifestations associated with some PIDs, such as thrombocytopenia or hemolytic anemia. (74,80,81)

**Chart 1. Primary immunodeficiencies in which immunoglobulin replacement is indicated**

<table>
<thead>
<tr>
<th>Ig indication level</th>
<th>Primary immunodeficiencies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Required and immediate start</td>
<td>X-linked and autosomal recessive agammaglobulinemia</td>
</tr>
<tr>
<td></td>
<td>Common variable immunodeficiency</td>
</tr>
<tr>
<td></td>
<td>Severe combined immunodeficiencies</td>
</tr>
<tr>
<td></td>
<td>X-linked and autosomal recessive hyper-IgM</td>
</tr>
<tr>
<td></td>
<td>Wiskott-Aldrich syndrome</td>
</tr>
<tr>
<td></td>
<td>NEMO deficiency and IKKβ</td>
</tr>
<tr>
<td></td>
<td>WHIM syndrome</td>
</tr>
<tr>
<td></td>
<td>Reticular dysgenesis</td>
</tr>
<tr>
<td>Depends on confirmation of diagnosis and severity of clinical condition</td>
<td>IgG subclass deficiency</td>
</tr>
<tr>
<td></td>
<td>Specific antibody deficiency</td>
</tr>
<tr>
<td></td>
<td>X-linked lymphoproliferative syndrome</td>
</tr>
<tr>
<td>Possible</td>
<td>Transient hypogammaglobulinemia of infancy*</td>
</tr>
<tr>
<td></td>
<td>Ataxia-telangiectasia</td>
</tr>
<tr>
<td></td>
<td>DiGeorge syndrome</td>
</tr>
<tr>
<td></td>
<td>Hyper-IgE syndrome</td>
</tr>
<tr>
<td></td>
<td>IgA + IgG2 and/or IgG4* deficiency</td>
</tr>
</tbody>
</table>

Despite having increased in recent years, the use of Ig in patients with secondary hypogammaglobulinemia (Chart 2) must be further investigated and is indicated in case of lower levels of serum IgG and/or documented impairment of antigen-specific antibody production and/or presence of relevant infections. A condition that has become more frequent in recent years is hypogammaglobulinemia associated with the use of rituximab, an anti-CD20 monoclonal antibody indicated for some autoimmune diseases, lymphoproliferative syndromes, or refractory nephrotic syndrome. This type of hypogammaglobulinemia affects up to 50% of patients, especially those on regular use of rituximab; is symptomatic in less than 10% of cases, and can persist for a long time requiring Ig replacement, either intravenous or subcutaneous. Persistent hypogammaglobulinemia may occur in a small group of genetically predisposed patients on rituximab.

Numerous studies showed a reduction in infections and mortality rates, and an overall improvement of health status and quality of life promoted by intravenous Ig replacement in PID patients.

We searched the literature and found a number of studies with similar or even better results with the use of subcutaneous Ig, especially in regard to improved quality of life. This route has also been shown effective and safe in children, elderly (even those on anticoagulation and antiplatelet therapy), pregnant women and obese patients at the same dose recommended for intravenous use.

Although replacement therapy with human Ig showed to be effective in a specific group of PIDs, it must also be considered for other PIDs in case of documented impairment of antibody production and presence of recurrent and/or severe infections. This therapy is safe and effective when administered either intravenously or subcutaneously.

### PRODUCTION

Ever since the first method for plasma protein fractionation using ethanol was introduced by Cohn-Oncley in the 1940’s, a series of improvements have been made to the production of Ig, leading to enhanced safety and tolerability. This process allowed for higher doses to be used intravenously with better clinical management of patients.

The immunoglobulin is purified from human plasma obtained from thousands of donors, ensuring a broad spectrum of protective antibodies. On the other hand, this could increase the theoretical risk for transmission of blood-borne pathogens, but this risk is eliminated by quarantining the donated blood and applying multiple purification steps. Different manufacturers use different combinations of precipitation, filtration, and chromatography to improve product purity (reaching an IgG concentration over 95%).

The diverse preparations also contain a small amount of IgA and traces of IgM.

The products available differ in their physicochemical characteristics (presentation, concentration, osmolarity and pH) and excipients (preservatives and IgG aggregation inhibitors). The latest products are safe from the standpoint of infection transmission; they are stabilized with amino acids rather than sugars, have lower sodium concentrations and IgA content under 50mg/ml.

The immunoglobulins are not generic products. The characteristics of each product must be considered at the time of prescription, as shown below, and switching must be avoided, except when indicated by the physician.

---

**Chart 2. Causes of secondary hypogammaglobulinemia**

<table>
<thead>
<tr>
<th>Disease-related</th>
<th>Secondary to the use of drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>B-cell disorders</td>
<td>Multiple myeloma, chronic lymphocytic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma</td>
</tr>
<tr>
<td>Protein-losing disorders</td>
<td>Nephrotic syndrome, protein-losing enteropathy and large burns</td>
</tr>
<tr>
<td>Lymphatic circulation-related diseases</td>
<td>Intestinal lymphangiectasis, chylothorax, and Proteus syndrome</td>
</tr>
<tr>
<td>Infectious diseases</td>
<td>HIV (in children), congenital infections due to rubella, cytomegalovirus, Epstein-Barr virus and toxoplasmosis</td>
</tr>
<tr>
<td>Diseases related to increased immunoglobulin catabolism</td>
<td>Myotonic dystrophy and hypersplenism</td>
</tr>
</tbody>
</table>

**Secondary to the use of drugs**

- **Immunosuppressants**: Corticosteroids, cyclophosphamide, acetyl mycophenolic acid, and cyclosporine
- **Anticonvulsants**: Carbamazepine, phenytoin, lamotrigine and sodium valproate
- **Immunobiologicals**: Rituximab, belimumab, imatinib, dasatinib, and atacicept
- **Other drugs**: Fenclofenac, chloroquine, captopril, sulfasalazine, gold salts, chlorpromazine and D-penicillamine

**MODE OF USE (ADMINISTRATION ROUTES, DOSES AND INTERVALS)**

Human Ig can be administered as intramuscular, intravenous and subcutaneous injections. Considering the rate of adverse effects and the limited volume that can be used, the intramuscular route is no longer used.

The standard loading dose of intravenous Ig is 400 to 600mg/kg/dose, starting at every 21 days. The relation between intravenous Ig doses, serum IgG concentrations and clinical control was demonstrated in several studies, but we must remember that the metabolism of the administered IgG varies among different individuals. Considering the importance of individualizing therapy, the doses and infusion intervals must be adjusted according to the clinical response and IgG concentrations obtained for each patient. Higher doses between 600 and 800mg/kg/dose (or up to 1,200mg/kg) may be required and are particularly indicated in case of chronic lung and/or sinus disease. Moreover, Ig is better metabolized during infections and autoimmune/inflammatory diseases, as well as with losses due to comorbidities or PID complications, or yet, in patients with neonatal Fc receptor promoter gene polymorphisms. Therefore, greater doses of Ig may be required, even if temporarily, in acute infections (increased IgG catabolism), severe and/or persistent diarrhea (gastrointestinal loss) or hypersplenism (sequestration).

Increase of serum concentrations with intravenous administration occurs within a few hours at about 100 to 200mg/dL for every 100mg/kg immunoglobulin administered, decreasing rapidly through tissue redistribution within the first few days, with half life around 21 to 28 days (Figure 1). As good clinical control and stable serum IgG concentrations are established, intravenous Ig infusions can be performed every 28 days. Stable IgG values are usually achieved within 3 (or up to 6) months of infusions.

Patients with very low IgG concentrations (<200mg/dL) are initially treated with intravenous Ig, often at initial doses of 800 to 1,000mg/kg, leading to a faster increase in serum concentrations.

Subcutaneous Ig is used at the same dose as intravenous Ig – about 400 to 600mg/kg/month, i.e., approximately 100 to 150mg/kg every week. The increase in serum IgG concentrations was estimated at 84.4mg/dL for each 100mg/kg/month increase in the subcutaneous Ig dose. Blood IgG concentrations increase less rapidly than with intravenous infusions, peaking at 2 to 4 days. When starting subcutaneous administration, shorter intervals are recommended as follows: 100mg/kg for 5 consecutive days in the first week, or twice-weekly in the first 2 weeks. Serum IgG concentrations are more stable with subcutaneous Ig and reached within 6 to 10 weeks of use (Figure 1). The interdose interval may go from fortnightly to daily, using infusion pumps or push. There has been recent evidence showing that higher doses of subcutaneous Ig, as has been established for intravenous Ig, are related with superior clinical control of patients.

In patients who wish to switch from intravenous to subcutaneous, we must wait a quarter of the previous monthly dose, starting subcutaneous infusions one to two weeks after the last intravenous infusion.

Subcutaneous administration should be preferably in the abdomen, but can also be given in the arms or thighs, without the need for site rotation. Local skin hygiene must be performed with alcohol or chlorhexidine. Local anesthetics or ice may be applied to reduce pain if necessary. There is no need to use gloves, but proper hand washing is critical. The infusion can be administered in two to four sites, simultaneously or sequentially, weekly or every two weeks. When using infusion pumps, the infusion rate must be 0.1 to 0.25mL/kg/hour/site, reaching up to 15mL/hour/site initially, and then a maximum of 25mL/hour/site. In case of more frequent administration by push, doses can be daily, twice or three times per week, or even weekly, with adequate safety and a shorter administration time when compared with pumps. Administration requires 1 to 10mL syringes with 25 to 23 gauge wing sets.
4 to 6mm needles for children and 9 to 15mm needles for adults,\(^{(108,112,113)}\) or special perpendicular needles,\(^{(20,117)}\) at a rate of 1ml/minute.\(^{(35)}\) The total volume applied per site depends largely on the individual tolerability and also varies according to the product, dose and administration time.\(^{(67,135,136)}\) In children, depending on the weight and age group, it is usually possible to give up to 10 to 20mL per site, whereas in adults, 30 to 40mL/site or up to 80mL, in some cases.\(^{(27,48,67,132,134,135)}\) A recent survey in Europe showed that most patients receive about 20mL per site with good tolerability.\(^{(134,138)}\)

A new product for subcutaneous use, already commercially available though not in Brazil, includes the application of hyaluronidase first and then (10 minutes later) the Ig solution, using the same route, allowing for a higher infusion volume per site.\(^{(139,140)}\) In this setting, it is possible to inject subcutaneous Ig every 21 to 28 days, just like intramuscular injections, with appropriate safety and good clinical results.\(^{(19)}\) Doses must be gradually increased over 7 weeks, which limits the use of this product when initial IgG levels are too low (<200mg/dL). In countries where this product is available, it has not yet been released for use in pregnant women and patients under 18 years of age.\(^{(67)}\)

Studies indicate that Ig therapy is safe during pregnancy, both intravenously or subcutaneously.\(^{(111,141)}\) Doses should be increased according to the clinical control and serum IgG concentrations achieved. Although the IgG given to pregnant women can cross the placenta and passively protect the fetus, the dose must be increased (20 to 30%) in the last trimester of pregnancy, to ensure adequate levels of antibodies to the newborn.\(^{(111,119,142)}\)

Therapy must continue throughout the patient’s life, except in those subjected to hematopoietic stem cell transplantation, and in patients with unspecified hypogammaglobulinemia, who can regain the ability to produce Ig.\(^{(74,79,119)}\) In those cases, infusions can be given at increasingly longer intervals, with close monitoring of the patient and serum IgG values, until they can be discontinued.\(^{(143)}\) However, there is no consensus in the literature on how to proceed in these situations.

### Adverse Effects, Prevention, Treatment and Reporting

Treatment with Ig is quite safe, but adverse effects have been described in 1 to 81% of patients or infusions; 30 to 40% of patients; and 5 to 15% of infusions.\(^{(144)}\) They can be mild, moderate or severe,\(^{(145,146)}\) immediate (during or shortly after infusion) or late (hours to days after infusion).\(^{(147)}\) Those considered mild do not cause any changes to vital signs and are resolved with symptomatic drugs without the need to stop the infusion. If signs and symptoms progress and/or persist requiring interruption of the infusion, the adverse effects are considered moderate. Severe adverse effects require immediate discontinuation of the drug and implementation of urgent therapeutic measures.\(^{(145,146)}\)

Most adverse events are mild and immediate, occurring within the first infusions, are related to the rate of infusion, and are rapidly reversible.\(^{(115,145-152)}\)

Headache, fever, malaise, flu-like symptoms, nausea, chills, fatigue, myalgia, low back pain, tachycardia, blood pressure changes and erythroderma are the most common events.\(^{(115,144,146,147,149,152)}\)

Severe reactions occur in less than 1% of infusions and usually with higher doses indicated for autoimmune and inflammatory diseases.\(^{(115,144,152,153)}\)

The exact pathophysiology of adverse events is still unknown. Some possibilities have been raised over the years, such as formation of IgG aggregates, interaction between the infused IgG and microbial antigens circulating in patients leading to formation of immune complexes, and reaction to vasoactive plasma components, contaminants, or other ingredients used during processing.\(^{(115,116,144,147,149)}\)

Anaphylactic-type reactions mostly do not involve IgE. They usually evolve with hypertension instead of hypotension, and are less severe in subsequent infusions.\(^{(116,144,151)}\) IgE-mediated anaphylaxis is a very rare event in patients with absence of IgA and preserved IgE production.\(^{(144)}\) In these cases, the use of low-IgA intravenous preparations or subcutaneous Ig infusions is indicated.\(^{(16,116,154)}\) However, there is no need to assess the presence of anti-IgA antibodies before starting Ig therapy.\(^{(144,154)}\)

Although rare, there are descriptions of neurological, respiratory, cardiovascular, gastrointestinal, renal, skin and blood abnormalities including headaches, aseptic meningitis, dyspnea, bronchospasm, transfusion-related acute lung injury (TRALI), hypotension or hypertension, arrhythmias, nausea, vomiting, diarrhea, renal failure, hives, skin rash, pruritic dermatosis, hemolytic anemia and thromboembolic events (Chart 3).\(^{(16,75,115,144,147,149,151,153,155)}\)

Some factors are associated with a higher risk of adverse effects and are listed in chart 4.\(^{(144,147,59,116,144,146,148,151-153,155,156)}\) It is worth noting that the presence of adverse events varies between different
products, or even between different batches of the same product. Some patients have adverse effects with one or more Ig products, but not all of them.\(^{(144)}\)

Considering the predisposing factors presented, proper measures must be taken to prevent adverse effects resulting from intravenous Ig infusions (Chart 5).\(^{(1,47,116,146,148,151,157)}\)

Most adverse effects can be resolved by reducing the rate or briefly stopping the infusion, and by giving analgesics and/or anti-histamines.\(^{(5,146,147,151)}\) Some patients may require corticosteroids.\(^{(146,149,158)}\)

In case of adverse reactions during intravenous administration, proper measures must be taken for future infusions (Chart 6).\(^{(146,147,151,157)}\)

---

### Chart 3. Types and frequency of adverse effects associated with administration of intravenous immunoglobulin

<table>
<thead>
<tr>
<th>Symptoms and signs</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Related to infusion rate</td>
<td></td>
</tr>
<tr>
<td>Chills</td>
<td>Frequent</td>
</tr>
<tr>
<td>Headache</td>
<td>Frequent</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>Frequent</td>
</tr>
<tr>
<td>Chest pain or tightness</td>
<td>Frequent</td>
</tr>
<tr>
<td>Back pain</td>
<td>Frequent</td>
</tr>
<tr>
<td>Fatigue and malaise</td>
<td>Frequent</td>
</tr>
<tr>
<td>Fever</td>
<td>Frequent</td>
</tr>
<tr>
<td>Hypotension or hypertension</td>
<td>Frequent</td>
</tr>
<tr>
<td>Myalgia</td>
<td>Frequent</td>
</tr>
<tr>
<td>Nausea and vomiting</td>
<td>Frequent</td>
</tr>
<tr>
<td>Prutitus</td>
<td>Frequent</td>
</tr>
<tr>
<td>Skin rash and hives</td>
<td>Frequent</td>
</tr>
<tr>
<td>Flu-like symptoms</td>
<td>Frequent</td>
</tr>
<tr>
<td>Tachycardia</td>
<td>Frequent</td>
</tr>
<tr>
<td>Central nervous system</td>
<td></td>
</tr>
<tr>
<td>Aseptic meningitis</td>
<td>Rare</td>
</tr>
<tr>
<td>Severe headache</td>
<td>Rare</td>
</tr>
<tr>
<td>Renal</td>
<td>Rare</td>
</tr>
<tr>
<td>Acute renal failure (acute tubular necrosis)</td>
<td>Rare (usually associated with sucrose as a stabilizer)</td>
</tr>
<tr>
<td>Azotemia</td>
<td>Rare</td>
</tr>
<tr>
<td>Thromboembolic events</td>
<td></td>
</tr>
<tr>
<td>Thrombosis and cerebral infarction</td>
<td>Rare</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>Rare</td>
</tr>
<tr>
<td>Pulmonary thromboembolism</td>
<td>Rare</td>
</tr>
<tr>
<td>Posterior leukoencephalopathy syndrome</td>
<td>Rare</td>
</tr>
<tr>
<td>Other</td>
<td></td>
</tr>
<tr>
<td>Anti-IgA IgE-mediated anaphylaxis</td>
<td>Very rare</td>
</tr>
<tr>
<td>Abnormal heart rhythm</td>
<td>Isolated reports (very rare)</td>
</tr>
<tr>
<td>Coagulopathy</td>
<td>Isolated reports (very rare)</td>
</tr>
<tr>
<td>Hemolysis – alloantibodies against A and B blood types</td>
<td>Isolated reports (very rare)</td>
</tr>
<tr>
<td>Cryoglobulinemia</td>
<td>Isolated reports (very rare)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>Isolated reports (very rare)</td>
</tr>
<tr>
<td>Alopecia</td>
<td>Isolated reports (very rare)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>Isolated reports (very rare)</td>
</tr>
<tr>
<td>Non-infectious hepatitis</td>
<td>Isolated reports (very rare)</td>
</tr>
</tbody>
</table>


### Chart 4. Factors associated with a greater rate of adverse effects of intravenous immunoglobulin

- Presence of infections
- Fever with no apparent source
- Dehydration
- Obesity
- Age over 65 years
- High blood pressure, heart disease or kidney disease
- Concomitant use of nephrotoxic drugs
- Hypercoagulable states
- First infusions
- Long interval between infusions
- Product switching
- Products with high concentrations (and high osmolarity)
- Products with high sodium and/or sugar content
- High rate of infusion
- Higher doses

### Chart 5. Measures to prevent adverse effects of intravenous immunoglobulin

- Control of predisposing factors: treat infectious processes and slow down infusion in case of major infection, avoid product switching, avoid long periods between infusions
- Pre-hydration (30 minutes prior) with 0.9% saline solution, 10 to 20mL/kg in children, and 500mL in adults
- Allow product to reach room temperature
- Properly reconstitute lyophilized products
- Monitor vital signs every 20 to 30 minutes
- Slow infusion rate, particularly in first infusions, and using infusion pumps, whenever possible. Start at 0.01mL/kg/minute (0.5 to 1mg/kg/minute), increasing gradually (every 15 to 30 minutes) to 0.02mL/kg/min, 0.04mL/kg/min, 0.06mL/kg/min up to 0.08mL/kg/min (4 to 8mg/kg/min, respectively for products at 5 and 10%), over 3 to 6 hours
- A scaled regimen with shorter intervals can be used in subsequent infusions, or even continuous infusion, as tolerated by the patient
- Observe for 30 to 60 minutes after completion, before releasing the patient

### Chart 6. Measures for secondary prevention of adverse reactions to intravenous immunoglobulin

- Slower rate of infusion in patients with prior reaction
- Pre-medication with analgesics and/or nonsteroidal anti-inflammatory drugs, H1 (and anti H2) antihistamines, and corticosteroids
- Pre-hydration with 0.9% saline solution
- Switch product or consider subcutaneous Ig in case of major reactions with no response to symptomatic drugs

Ig: immunoglobulin.
Special attention is needed for patients with comorbidities, such as heart diseases, kidney diseases, liver diseases, coagulation disorders (thrombophilia), and diabetes mellitus. In these situations, some product characteristics, such as the presence of sugars, osmolality, sodium, among others, must be assessed. Chart 7 describes the most relevant factors according to the associated morbidity, and chart 8 lists the products available to facilitate this choice.\(^5,17,147\)

Subcutaneous administration is rarely associated with systemic adverse effects, which occur in less than 1% of infusions.\(^42,72,144\) Approximately 75% of patients

---

**Chart 7. Immunoglobulin characteristics to be assessed before prescribing commercial intravenous immunoglobulin products, considering comorbidities and age groups**

<table>
<thead>
<tr>
<th>Comorbidities and age groups</th>
<th>Characteristics of Ig products</th>
<th>Volume</th>
<th>Osmolarity</th>
<th>Sodium</th>
<th>Sugar</th>
<th>Other stabilizers</th>
<th>pH</th>
<th>IgA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>-</td>
<td>x Glycine</td>
<td>x</td>
<td>-</td>
</tr>
<tr>
<td>Renal failure</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>-</td>
<td>- Sucrose-glucose</td>
<td>x</td>
<td>-</td>
</tr>
<tr>
<td>Anti-IgA antibodies</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thromboembolic risk</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>x Glucose-maltose</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hyperprolinemia</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>x L-proline</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hereditary fructose intolerance</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>- Sorbitol</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Com allergy</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>x Maltose</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Seniors</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Newborn/children</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>


IgA: immunoglobulin A

---

**Chart 8. Human immunoglobulin, commercial products available in Brazil**

<table>
<thead>
<tr>
<th>Brand name</th>
<th>Manufacturer/distributor</th>
<th>Sugar</th>
<th>Sodium</th>
<th>Osmolarity</th>
<th>pH</th>
<th>IgA concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intravenous use</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endobulin Kiovig 10% solution†</td>
<td>Baxter Hospitalar</td>
<td>Does not contain</td>
<td>Does not contain</td>
<td>240-300mOsmol/kg</td>
<td>4.6-5.1</td>
<td>Maximum: 0.14mg/mL</td>
</tr>
<tr>
<td>Flebogamma DIF 5% solution</td>
<td>Grifols</td>
<td>D-Sorbitol</td>
<td>&lt;3.2mmol/L</td>
<td>32±4.5mOsmol/kg</td>
<td>5.6±0.1</td>
<td>&lt;0.003mg/mL</td>
</tr>
<tr>
<td>Flebogamma DIF 10% solution</td>
<td>Grifols</td>
<td>D-Sorbitol</td>
<td>&lt;3.2mmol/L</td>
<td>342±7.2mOsmol/kg</td>
<td>5.5±0.1</td>
<td>&lt;0.003mg/mL</td>
</tr>
<tr>
<td>Blau* Immunoglobulin</td>
<td>Blausiegel</td>
<td>Maltose</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>OCTAGAM® 5% solution†</td>
<td>Octapharma</td>
<td>Maltose</td>
<td>≤0.015mmol/mL</td>
<td>310-380mOsmol/kg</td>
<td>5.1-6.0</td>
<td>&lt;0.2mg/mL</td>
</tr>
<tr>
<td>OCTAGAM® 10% solution</td>
<td>Octapharma</td>
<td>Maltose</td>
<td>≤0.03mmol/mL</td>
<td>≥240mOsmol/Kg</td>
<td>4.5-6.0</td>
<td>&lt;0.4mg/mL</td>
</tr>
<tr>
<td>Privigen</td>
<td>CSL Behring</td>
<td>Does not contain</td>
<td>Does not contain</td>
<td>320mOsmol/kg</td>
<td>4.8</td>
<td>≤0.025g/L</td>
</tr>
<tr>
<td>TEGELINE® 5% lyophilized powder</td>
<td>LFB</td>
<td>Sucrose</td>
<td>2mg/mL NaCL</td>
<td>340-480mOsmol/kg</td>
<td>4.0-7.4</td>
<td>Maximum: 17mg/g</td>
</tr>
<tr>
<td>TEGELINE® NEWY 5% solution</td>
<td>LFB</td>
<td>Mannitol</td>
<td>Does not contain</td>
<td>270-330mOsmol/kg</td>
<td>4.0-7.4</td>
<td>Maximum: 0.022mg/mL</td>
</tr>
<tr>
<td>Vigam*</td>
<td>Meizler</td>
<td>Sucrose</td>
<td>&lt;160mmol/L</td>
<td>&gt;240mOsmol/kg</td>
<td>-</td>
<td>&lt;100mcg/mL</td>
</tr>
<tr>
<td><strong>Subcutaneous use</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endobulin Kiovig 10% solution†</td>
<td>Baxter Hospitalar</td>
<td>Does not contain</td>
<td>Does not contain</td>
<td>240-300mOsmol/kg</td>
<td>4.6-5.1</td>
<td>Maximum: 0.14mg/mL</td>
</tr>
<tr>
<td>Hizentra</td>
<td>CSL™ Behring</td>
<td>Does not contain</td>
<td>Does not contain</td>
<td>380mOsmol/kg</td>
<td>4.8</td>
<td>Maximum content: 50mcg/L</td>
</tr>
</tbody>
</table>

Source: data obtained from manufacturers.

\(^*\) Data obtained from product inserts. \(^†\) Product previously approved only for intravenous use, recently released for subcutaneous use (Resolution 1789 of June 19, 2015, published in the Official Federal Gazette of June 22, 2015). \(^‡\) Product exclusively for subcutaneous use as recently approved by the National Health Surveillance Agency (ANVISA) (Resolution 2617 of September 18, 2015, published in the Official Federal Gazette of September 21, 2015).
The manufacturers, according to Decree 6523, of 31 July 2008, by the Chief of Staff, must have a customer service call center (SAC) with lines readily available. And physicians and patients must be able to use this call center to report signs and symptoms related with the use of different human Ig presentations commercially available.

**CHOOSING BETWEEN INTRAVENOUS AND SUBCUTANEOUS ADMINISTRATION**

Treatment of patients with PID as well as other patients, particularly those with chronic diseases, must always be individualized to achieve good control of the disease and its manifestations, as well as good quality of life, and must be as adjusted as possible to patient characteristics and preferences.

Each of the routes, intravenous or subcutaneous, has interesting features (Chart 9) depending on factors related to the disease, the patient and their family, as well as their socioeconomic level. What can be described as a disadvantage for a certain patient can be quite beneficial in other situations. For example, monthly intravenous application in a hospital could be interesting for patients with more severe disease, whose family does not adhere to the treatment, in which case close clinical monitoring is critical.

**Chart 9. Comparison between intravenous and subcutaneous immunoglobulin**

<table>
<thead>
<tr>
<th>Items for comparison</th>
<th>Intravenous Ig</th>
<th>Subcutaneous Ig*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infusion frequency</strong></td>
<td>Every 3 to 4 weeks</td>
<td>From daily to every 2 weeks</td>
</tr>
<tr>
<td><strong>Infusion volume</strong></td>
<td>Large</td>
<td>Small</td>
</tr>
<tr>
<td><strong>Infusion time</strong></td>
<td>2 to 6 hours</td>
<td>30 to 90 minutes (pump)</td>
</tr>
<tr>
<td><strong>Use of high doses</strong></td>
<td>Possible</td>
<td>Limited by volume/sites and number of sites</td>
</tr>
<tr>
<td><strong>Control of serum IgG levels</strong></td>
<td>Before each infusion</td>
<td>Anytime</td>
</tr>
<tr>
<td><strong>Pharmacokinetics</strong></td>
<td>Rapid rise in IgG levels after infusion, with subsequent fluctuating levels and wear-off effect</td>
<td>Slower increase in IgG levels, with subsequent stable levels and no wear-off effect</td>
</tr>
<tr>
<td><strong>Infusion</strong></td>
<td>Requires venous access secured by qualified professionals at a healthcare unit</td>
<td>No need for venous access, can be applied by the patient, caregiver or healthcare professional after training, can be administered at home</td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td>Effective in infection control</td>
<td>Effective in infection control</td>
</tr>
<tr>
<td><strong>Infusion site reactions</strong></td>
<td>Rare</td>
<td>Frequent but usually mild and improving with time</td>
</tr>
<tr>
<td><strong>Systemic reactions</strong></td>
<td>Rare, more prevalent in the first infusions and depending on the presence of comorbidities</td>
<td>Overall improvement in the quality of life of patients who want independence and fewer trips to the healthcare unit, or patients who experience adverse events with intravenous Ig</td>
</tr>
<tr>
<td><strong>Level of patient satisfaction</strong></td>
<td>Generally preferred by patients and caregivers who do not wish to self-administer or want less frequent applications</td>
<td>Preferable in the presence of some comorbidities, difficult venous access, poor clinical control or significant adverse effects with intravenous infusion, difficult access to the healthcare facility; indicated for patients with good treatment adherence, good hygiene conditions at home, and trained and motivated to perform administration</td>
</tr>
<tr>
<td><strong>Patient characteristics</strong></td>
<td>Preferable in patients of low socioeconomic and education level requiring closer clinical follow-up, with poor adherence to the treatment, with extensive or severe skin lesions, coagulation disorders, and patients resistant to self-administration</td>
<td></td>
</tr>
<tr>
<td><strong>Cost</strong></td>
<td>Higher (product, healthcare facility, infusion supplies, healthcare staff)</td>
<td>Lower (product, infusion supplies and pump)</td>
</tr>
</tbody>
</table>


Ig: immunoglobulin; IgG: immunoglobulin G.
The intravenous route allows for faster achievement of higher IgG concentrations, has documented efficacy and accommodates longer administration intervals. In addition, by infusing at the hospital, it is possible to have patients under stricter supervision by the healthcare staff. However, it is necessary to secure venous access, which can be difficult in many patients, and the procedure must be preferably performed at a hospital, requiring monthly visits. There is also systemic adverse effects, even if not frequent. The serum IgG concentrations obtained are unstable, with significant reduction 15 to 20 days after administration, sometimes associated with symptoms such as fatigue and malaise (wear-off effects).(48,130)

With subcutaneous use, serum IgG concentrations are more stable, allowing for easier application, without the need for venous access. In some countries, there is no need to visit the healthcare facility, offering greater independence to patients and caregivers.(48,161) Other countries have vast experience with the subcutaneous route, with proven efficacy and safety,(31,35,104,160,162) including fewer systemic adverse effects.(31,32,130,163) Furthermore, there are many studies demonstrating improved quality of life with subcutaneous Ig replacement.(35,59,68,102,164) Serum IgG concentrations rise more slowly, which could be considered a disadvantage in cases of very low initial IgG levels, but is an advantage in patients with hypersplenism or high renal/gastrointestinal loss.(165) There is a need for training and engagement of patients and/or caregivers, which is usually possible to be achieved over 4 to 6 weeks, and close monitoring of the infusion technique must be maintained subsequently.(27,104,137,162) There are several studies,(31,166-171) including national studies,(172) pointing to a considerable cost reduction associated with subcutaneous administration, particularly when performed at home.

Intravenous Ig is effective, safe, leads to a rapid rise in IgG concentrations, and can be obtained via the public healthcare system in Brazil (SUS - Sistema Único de Saúde) as well as the private system. Subcutaneous Ig has been offered only by the private healthcare system. The classic indications for subcutaneous Ig are problems with intravenous infusion: inadequate IgG concentrations, poor clinical control, wear-off, systemic adverse effects, difficulty securing venous access, or difficult access to healthcare facilities.(42,116,173) Individual aspects which can improve the quality of life of patients must also be considered when this choice is made, as well as reduction of treatment costs.(18,27,41,57,71,116,173)

MONITORING
Clinical and laboratory monitoring of patients must be performed to ensure good disease control and watch for complications and potential side effects of the therapy. It is critical to record the product brand, the lot number and the expiration date of every infusion.(52,59)

Regular clinical evaluations must be performed at variable intervals, depending on the severity of the PID, as well as personal, familial and social characteristics of the patient. It is important to observe the number, type and severity of infections, use of antibiotics, need for hospitalizations, attendance of every day activities (school or work), new complaints and symptoms, and presence of comorbidities, in addition to performing a complete physical examination.(52,77)

The following tests are recommended before the start of infusions: Ig levels (A, M, G and E), evaluation of vaccine response and lymphocyte count (T; B and NK), complete blood count, direct Coombs, kidney and liver function, and PCR for infectious agents (because these patients have impaired antibody production, serologic tests for infectious agents are not indicated).(47,57,116,144,157)

Laboratory control must be carried out every 3 to 6 months in the first year, and then every 6 to 12 months depending on the clinical condition. It must include(5,72,116) serum IgG, and also IgA and IgM, particularly in very young patients, in order to detect recovery in patients with unspecified hypogammaglobulinemia; complete blood count; sedimentation rate; C-reactive protein; direct Coombs; and kidney and liver function tests.

APPROVED PRODUCTS
The products approved for sales in Brazil are presented in chart 8.

The use of intravenous human Ig in antibody immunodeficiencies was regulated by the Clinical Protocol and Therapeutic Guidelines (PCDT) published in the SAS/MS Therapeutic Guidelines (PCDT) published in the SAS/MS Ordinance 495, of September 11, 2007, http://bvsms.saude.gov.br/bvs/saudelegis/sas/2007/prt0495_11_09_2007.html. The document was subjected to public consultation nº. 22 of May 10, 2010, (http://bvsms.saude.gov.br/bvs/saudelegis/sas/2010/cop0022_10_05_2010.html) by the Health Care Department (Ministry of Health) with a proposal to update this PCDT which has not yet been published. The PDIs for which Ig therapy is indicated, according to this PCDT update proposal, are listed in chart 10.
The use of subcutaneous or intravenous Ig at home is not yet approved in our country, despite it being common in other countries, (27,29,37-39,41,161) as well as demonstratedly effective and safe. (25,99,107,145,162,174) A recent survey conducted by the International Patient Organisation for Primary Immunodeficiencies (IPOPI), in 20 countries, showed that among 300 patients, 53% received intravenous Ig and 45%, subcutaneous Ig, and that 14% of patients on intravenous Ig and 94% of patients on subcutaneous Ig received infusions at home. (138)

CONCLUSION
Ever since the 1st Brazilian Consensus on the Use of Human Immunoglobulin in Patients with Primary Immunodeficiencies, published in 2010, several new primary immunodeficiencies have been described. Since then, new human immunoglobulin products have been made available in our country, with different compositions and administration routes. Therefore, the recommendations for the use of immunoglobulin in our country need to be updated.

This work provides new knowledge on the products available, their indications, mode of use and monitoring information.

The indication of each product depends on clinical and laboratory characteristics of patients, and treatment individualization and patient monitoring are critical, irrespective of the brand or route of administration of the product.

ACKNOWLEDGEMENTS
For the final review of the text, we thank Fernanda Pinto Mariz and Flavia Amendola Anísio de Carvalho, Allergy and Immunology specialists from the Brazilian Society of Allergy and Immunology.

REFERENCES


Erratum: II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

Erratum: II Consenso Brasileiro sobre o uso de imunoglobulina humana em pacientes com imunodeficiências primárias

Ekaterini Simões Goudouris¹, Almerinda Maria do Rego Silva², Aluce Loureiro Ouricuri³, Anete Sevcovic Grumach⁴, Antonio Condino-Neto⁵, Beatriz Tavares Costa-Carvalho⁶, Carolina Cardoso de Mello Prando⁷, Cristina Maria Kokron⁸, Dewton de Moraes Vasconcelos⁹, Fabiola Scancetti Tavares¹⁰, Gesmar Rodrigues Silva Segundo¹⁰, Irma Cecília Douglas Paes Barreto¹¹, Mayra de Barros Dorna¹², Myrthes Anna Maragna Toledo Barros¹², Wilma Carvalho Neves Forte¹²; in name of Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology


Page 6, stated: In this setting, it is possible to inject subcutaneous Ig every 21 to 28 days, just like intramuscular injections, with appropriate safety and good clinical results.¹⁹ It should be read: In this setting, it is possible to inject subcutaneous Ig every 21 to 28 days, just like intravenous injections, with appropriate safety and good clinical results.¹⁹

It the same article, page 8, stated: In chart 8, at the Osmolarity column, 32±4.5mOsm/kg. It should be read: In chart 8, at the Osmolarity column, 327±4.5mOsm/kg.